Literature DB >> 29615302

The Endothelial-Metabolic Axis: A Novel Cardiometabolic Disease Target.

Jason C Kovacic1.   

Abstract

Endothelial to mesenchymal transition (EndMT) involves cellular phenotypic switching from an endothelial to mesenchymal state. Interest in EndMT has been increasing with the appreciation that it has an important role in several cardiovascular diseases. New evidence indicates that fatty acid oxidation (FAO) and cell metabolism are major factors controlling this process.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EndMT; cardiovascular; endothelial; endothelial to mesenchymal transition; fatty acid oxidation; metabolic

Mesh：

Year:  2018        PMID： 29615302      PMCID： PMC6054799          DOI： 10.1016/j.tem.2018.03.015

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  8 in total

1.  A Metabolic Basis for Endothelial-to-Mesenchymal Transition.

Authors:  Jianhua Xiong; Hiroyuki Kawagishi; Ye Yan; Jie Liu; Quinn S Wells; Lia R Edmunds; Maria M Fergusson; Zu-Xi Yu; Ilsa I Rovira; Evan L Brittain; Michael J Wolfgang; Michael J Jurczak; Joshua P Fessel; Toren Finkel
Journal:  Mol Cell       Date:  2018-02-08       Impact factor: 17.970

2.  Structural development of endocardial cushions.

Authors:  R R Markwald; T P Fitzharris; F J Manasek
Journal:  Am J Anat       Date:  1977-01

3.  Cell contact during early morphogenesis in the chick embryo.

Authors:  R L Trelstad; E D Hay; J D Revel
Journal:  Dev Biol       Date:  1967-07       Impact factor: 3.582

Review 4.  Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease.

Authors:  Jason C Kovacic; Nadia Mercader; Miguel Torres; Manfred Boehm; Valentin Fuster
Journal:  Circulation       Date:  2012-04-10       Impact factor: 29.690

5.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

Review 6.  Obesity, inflammation and endothelial dysfunction.

Authors:  M Iantorno; U Campia; N Di Daniele; S Nistico; G B Forleo; C Cardillo; M Tesauro
Journal:  J Biol Regul Homeost Agents       Date:  2014 Apr-Jun       Impact factor: 1.711

7.  Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.

Authors:  Takahiro Seki; Kayoko Hosaka; Carina Fischer; Sharon Lim; Patrik Andersson; Mitsuhiko Abe; Hideki Iwamoto; Yanyan Gao; Xinsheng Wang; Guo-Hua Fong; Yihai Cao
Journal:  J Exp Med       Date:  2018-01-05       Impact factor: 14.307

8.  Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability.

Authors:  Solene M Evrard; Laura Lecce; Katherine C Michelis; Aya Nomura-Kitabayashi; Gaurav Pandey; K-Raman Purushothaman; Valentina d'Escamard; Jennifer R Li; Lahouaria Hadri; Kenji Fujitani; Pedro R Moreno; Ludovic Benard; Pauline Rimmele; Ariella Cohain; Brigham Mecham; Gwendalyn J Randolph; Elizabeth G Nabel; Roger Hajjar; Valentin Fuster; Manfred Boehm; Jason C Kovacic
Journal:  Nat Commun       Date:  2016-06-24       Impact factor: 14.919
  8 in total
  3 in total

Review 1.  Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Jason C Kovacic; Stefanie Dimmeler; Richard P Harvey; Toren Finkel; Elena Aikawa; Guido Krenning; Andrew H Baker
Journal:  J Am Coll Cardiol       Date:  2019-01-22       Impact factor: 24.094

Review 2.  Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy.

Authors:  Jaqueline S da Silva; Renata G J Gonçalves; Juliana F Vasques; Bruna S Rocha; Bianca Nascimento-Carlos; Tadeu L Montagnoli; Rosália Mendez-Otero; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

3.  Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.

Authors:  Jingjing Tian; Mingjun Zhang; Mengying Suo; Dian Liu; Xuyang Wang; Ming Liu; Jinyu Pan; Tao Jin; Fengshuang An
Journal:  J Cell Mol Med       Date:  2021-06-25       Impact factor: 5.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.